Comprehensive Overview: Cytokines, JAK1/JAK2 Pathways, Pathogens, Drugs, and Monitoring

By SWA

Introduction

In my ongoing battle with severe immunodeficiency-related symptoms, my search for answers began in earnest in 2010, when DNA testing confirmed mutations in JAK1 and JAK2. This pivotal discovery marked the start of my journey to uncover the most effective diagnostic tests, medications, and—most critically—gain a thorough understanding of their potential side effects. Over the decades, I have navigated a complex and challenging medical history, including long-term cortisol use for psoriasis since 1970, hydrocortisone therapy for adrenal insufficiency since 1979. Each of these experiences has shaped my understanding of immunodeficiency and its far-reaching impact on overall health.

In 2016, I experienced a life-threatening complication following L4-L5 spinal surgery, which resulted in sepsis caused by a rare and unusual bacteremia involving Staphylococcus epidermidis, Peptostreptococcus species, Staphylococcus caprae, and Corynebacterium species. Since then, I have faced persistent and challenging battles with recurring candida infections, further complicating my health journey.

More recently, in December 2021, I was diagnosed with von Willebrand Disease (types 2 and 5), antiphospholipid syndrome (APS), and lupus. These diagnoses, combined with an extreme cytokine reaction triggered by COVID-19, have required me to take Cetirizine to help manage the resulting immune dysregulation.
Through these experiences, I have gained critical insights into the complexities of immunodeficiency, the intricate interplay of cytokine pathways, and the far-reaching implications of various treatments. This knowledge extends beyond my personal journey—it is something I believe must be taken seriously by anyone navigating similar health challenges, as well as by the medical community as a whole.

Part 1: Cytokine Multiplex 18-Panel Test

What It Is:

The cytokine multiplex 18-panel test measures the levels of 18 cytokines in a single sample (e.g., blood, serum, plasma). It provides valuable insight into immune system regulation, inflammation, and disease progression.

How It Works:

The test uses multiplex immunoassay technology (e.g., Luminex xMAP), which employs color-coded beads coated with cytokine-specific antibodies.

  1. Microsphere Beads: Antibody-coated beads bind specific cytokines.
  2. Binding of Cytokines: Cytokines in the sample attach to their respective beads.
  3. Fluorescent Detection: A secondary antibody with a fluorescent marker binds to the captured cytokine.
  4. Data Acquisition: A Luminex analyzer measures fluorescence intensity, determining cytokine levels.

Cytokines Measured:

  • Pro-inflammatory: IL-1β, IL-2, IL-6, IL-8, IL-12, TNF-α, IFN-γ
  • Anti-inflammatory: IL-4, IL-10, IL-13
  • Chemokines: MCP-1 (CCL2), MIP-1α (CCL3), RANTES (CCL5)
  • Growth Factors: VEGF, GM-CSF, G-CSF
  • Others: IL-17, IL-15, IL-5

Applications:

  1. Immunology & Inflammation:

    • Autoimmune diseases (e.g., RA, lupus, MS).
    • Immune responses to infections (e.g., COVID-19, sepsis).
    • Chronic inflammatory conditions (e.g., asthma, IBD).

  2. Cancer Research:

    • Studying tumor microenvironments and immune evasion.

  3. Drug Development:

    • Monitoring immunomodulatory therapy efficacy.

  4. Transplant Medicine:

    • Detecting organ rejection early.

  5. Neurology/Psychiatry:

    • Exploring roles of cytokines in neurodegenerative diseases (e.g., Alzheimer's).

Advantages and Limitations:

  • Advantages: High throughput, sensitivity, cost-effective.
  • Limitations: Specialized equipment, cross-reactivity, limited detection range.

Part 2: JAK1 Inhibitors

What Are JAK1 Inhibitors?

JAK1 inhibitors are drugs targeting Janus Kinase 1 (JAK1), a key enzyme in the JAK-STAT signaling pathway. This pathway is essential for cytokine-mediated processes, including immune responses, inflammation, and cell growth.

Therapeutic Applications:

  • Autoimmune Diseases: RA, psoriasis, lupus, IBD.
  • Cancers: Linked to JAK-STAT dysregulation.
  • Chronic Inflammatory Conditions.

Full JAK1 Panel Analysis:

  1. Selectivity: Evaluates specificity for JAK1 versus JAK2, JAK3, TYK2.
  2. Potency: Measures inhibitor effectiveness in blocking JAK1.
  3. Cytokine Pathway Inhibition: Assesses JAK1-mediated cytokine signaling.
  4. Functional Assays: Tests biological impact in disease models.
  5. Toxicity & Off-Target Effects: Identifies adverse effects (e.g., anemia from JAK2 inhibition).
  6. PK/PD Studies: Determines absorption, metabolism, and duration of effect.

Key Components:

  • Cytokines Affected by JAK1:
    • Type I Interferons (IFN-α, IFN-β)
    • Type II Interferon (IFN-γ)
    • IL-6, IL-10, IL-12, IL-23
  • STAT Proteins: STAT1, STAT3, STAT5 phosphorylation reflects pathway activity.

Examples of JAK1 Inhibitors:

  • Upadacitinib (Rinvoq): Selective JAK1 inhibitor for RA, psoriasis, dermatitis.
  • Filgotinib: Under investigation for IBD and other conditions.
  • Baricitinib (Olumiant): Targets JAK1/JAK2, used in RA and severe COVID-19.

Challenges with JAK1 Inhibition:

  • Cytokine Redundancy: Blocking JAK1 may not fully inhibit cytokine activity.
  • Infection Risk: Immune suppression increases susceptibility to infections (e.g., TB, zoster).

Part 3: Pathogens and the JAK-STAT Pathway

Pathogen Activation of JAK1/JAK2:

Pathogens stimulate the JAK-STAT pathway by inducing cytokines and interferons that activate JAK1 and JAK2.

  1. Viruses:

    • SARS-CoV-2 (COVID-19): Activates JAK1/JAK2 via IL-6 and IFN-γ signaling, causing cytokine storms.
    • Hepatitis B/C Viruses: Trigger Type I IFN signaling but may manipulate it for immune evasion.
    • HIV: Dysregulates JAK-STAT to suppress immunity.

  2. Bacteria:

    • Mycobacterium tuberculosis: Stimulates IFN-γ signaling via JAK1/JAK2.
    • Staphylococcus aureus: Activates acute-phase cytokines (IL-6, IL-10).

  3. Parasites:

    • Plasmodium (Malaria): Activates IFN-γ but may contribute to severe inflammation.
    • Leishmania: Modulates JAK1/JAK2 to evade immunity.

  4. Fungi:

    • Candida albicans: Induces JAK1/JAK2 activation for antifungal responses.

Pathogen Exploitation of JAK-STAT Pathway:

  • Viruses: Suppress JAK-STAT for immune evasion.
  • Bacteria/Parasites: Manipulate pathways to persist or suppress immunity.

Part 4: Immunosuppressive Drugs and Cancer Risk

Drugs That Suppress Cytokine Activity:

  1. Immunosuppressants:

    • Corticosteroids: Chronic use may increase cancer risk.
    • Calcineurin Inhibitors (Cyclosporine, Tacrolimus): Raise lymphoma and skin cancer risk.

  2. Biologics (Cytokine Inhibitors):

    • Anti-TNF Agents (e.g., Infliximab): Associated with lymphoma and skin cancer.
    • IL-6 Inhibitors (e.g., Tocilizumab): May suppress immune surveillance.
    • JAK Inhibitors (e.g., Tofacitinib): Linked to malignancy risk, particularly lymphoma.

  3. Chemotherapy Drugs:

    • Suppress cytokine production and immune cell function.

Why Suppression Increases Cancer Risk:

  • Cytokines (e.g., TNF-α, IFN-γ): Crucial for activating T cells, inducing apoptosis, and preventing immune evasion.
  • Suppressing these cytokines weakens the immune system's ability to fight cancer.

Part 5: Monitoring for Side Effects of Immune Modulation

Frequent Tests:

  1. Routine Blood Work:

    • CBC: Monitors for leukopenia, anemia, and thrombocytopenia.
    • LFTs and Kidney Function Tests: Detect hepatotoxicity and nephrotoxicity.

  2. Cancer Screening:

    • Skin Exams: High risk with TNF inhibitors and transplant immunosuppressants.
    • Colonoscopy, Pap Smear, Mammograms: Based on cancer risk.

  3. Infection Monitoring:

    • TB Screening: Essential for biologics (e.g., anti-TNF, IL-6 inhibitors).
    • Hepatitis B/C and HIV Testing: Reactivation risk with immunosuppressants.

  4. Specialized Drug Monitoring:

    • Cyclosporine/Tacrolimus Levels: Avoid toxicity.
    • Methotrexate: Liver enzyme monitoring.

  5. Bone Density Tests:

    • For patients on corticosteroids to detect osteoporosis.

  6. Imaging Studies:

    • Chest X-rays/CT: Detect infections (e.g., TB, pneumonia) or malignancies.

Frequency of Monitoring:

  • First 3–6 Months: Every 2–4 weeks.
  • Long-Term: Every 3–6 months, depending on risk factors.

Key Takeaways

  • The cytokine multiplex test and JAK1 inhibitors are powerful tools for understanding and modulating immune responses.
  • However, cytokine suppression (e.g., JAK inhibitors, biologics) increases the risk of infections and malignancies.
  • Regular monitoring, tailored to the medication and patient, is critical to ensure safety and efficacy.

Medication side effects:
RINVOQ may cause serious side effects, including: https://www.rinvoq.com/side-effects

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right.
Library of Congress Card Number: LCN 00-192742
ISBN: 0-9703195-0-9 



 

Comments

Post a Comment

Popular posts from this blog

Is ME CFS connected to Spinal Muscular Atrophy (SMA)?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. After a 70-year journey filled with misdiagnoses and ineffective treatments, I finally discovered the true cause of my progressive muscle weakness. Throughout this time, I endured insults and was labeled lazy because of my inability to walk long distances, climb stairs, or carry heavy loads. I couldn’t ride a bike because I couldn’t sit on the saddle, and my school performance suffered due to struggles in sports. Instead of support, my parents urged me to work harder to strengthen my muscles, and doctors advised me to exerc...
Read more

Cytokine Storm, Mast Cell Activation Syndrome (MCAS), Endothelial Dysfunction and microclots/thrombosis?

By SWA
Could a virus be the stimulus for cytokine production?   It is well established, but rarely  tested, that a cytokine storm is an overactive immune response characterized by the excessive release of pro-inflammatory cytokines. ( ANA, CRP, and CBC tests are necessary) It can occur in various conditions, such as severe infections (e.g., COVID-19), (and other viruses), autoimmune diseases, and after certain treatments.  Serositis and lymphopenia are common features of systemic lupus erythematosus following SARS-CoV-2 infection: A case report and literature review These cells are called NKG2D+CD8+ T cells and researchers say their aggressive response is responsible for neurological damage suffered from infections beyond just Zika, like COVID-19 and even septic shock. The aggressive response is the result of the body producing large amounts of inflammatory proteins called cytokines, which in moderation help to coordinate the body’s response in battling an infection...
Read more

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more